Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours

[1] Hay T(2005)Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy Cancer Res 65 10145-10148

[2] Jenkins H(2008)Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin Clin Cancer Res 14 3916-3925

[3] Sansom OJ(2008)High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci USA 105 17079-17084

[4] Martin NM(2013)Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Breast Cancer Res 15 R88-3865

[5] Smith GC(2015)Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer J Clin Oncol 33 3858-1651

[6] Clarke AR(2017)Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol 18 1637-1663

[7] Evers B(2014)Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Ann Oncol 25 1656-415

[8] Drost R(2016)An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib Target Oncol 11 401-531

[9] Schut E(2016)Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours Cancer Chemother Pharmacol 78 525-2299

[10] de Bruin M(2016)Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two Phase I open-label studies Clin Ther 38 2286-423

[1] Hay T(2005)Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy Cancer Res 65 10145-10148

[2] Jenkins H(2008)Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin Clin Cancer Res 14 3916-3925

[3] Sansom OJ(2008)High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci USA 105 17079-17084

[4] Martin NM(2013)Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Breast Cancer Res 15 R88-3865

[5] Smith GC(2015)Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer J Clin Oncol 33 3858-1651

[6] Clarke AR(2017)Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol 18 1637-1663

[7] Evers B(2014)Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors Ann Oncol 25 1656-415

[8] Drost R(2016)An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib Target Oncol 11 401-531

[9] Schut E(2016)Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours Cancer Chemother Pharmacol 78 525-2299

[10] de Bruin M(2016)Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two Phase I open-label studies Clin Ther 38 2286-423